ETCAMAH
As listed in the register: ETCAMAH
75 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Camizestrant
- Made by
- Astrazeneca Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (ETCAMAH). It describes the substance, not this exact product.
Camizestrant is an estrogen receptor (ER) antagonist.
In vitro, camizestrant binds to the ligand binding domain of ERα, antagonizing the activity of ERα encoded by both wild-type ESR1 and mutated ESR1 and inducing proteasome-dependent degradation of ERα, without agonizing ERα.
Camizestrant is primarily metabolized by CYP3A and UGT1A4.
Effect of Food No clinically significant differences in camizestrant pharmacokinetics were observed following administration of a high-fat meal (951 calories, 58% fat) in healthy postmenopausal women.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-04
Safety of the active substance
From the US prescribing label for the same active substance (ETCAMAH). It describes the substance, not this exact product.
WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death ( 5.1, 5.2, 7.1 ).
The most common adverse reactions (≥ 20%), including laboratory abnormalities, with ETCAMAH in combination with a CDK4/6 inhibitor were decreased neutrophils, decreased leukocytes, decreased hemoglobin, decreased lymphocytes, decreased platelets, visual disturbances, and fatigue.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Netherlands1 matching products
Details
| Made by | Astrazeneca Canada Inc |
|---|---|
| Active substance | Camizestrant |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 75 mg |
| Form | tablet |
| Classification | L02BA05 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION RECOMMENDED |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02570572 |
| DPD drug code | 107271 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.